Skip to main content
Premium Trial:

Request an Annual Quote

Epitomics to Develop Antibodies for Mass Spec Assays in Support of CPTC

Premium

Antibody maker Epitomics this week announced that it has signed a contract with SAIC-Frederick to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer program.

The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma. The antibodies will be used for immuno-enrichment of target peptides in mass spec workflows like stable isotope standards and capture by anti-peptide antibodies, or SISCAPA, and immuno-MALDI mass spec.

Epitomics has completed the first phase of the project, which called for it to generate and affinity-purify polyclonal antibodies against the biomarkers. In the current phase it will generate monoclonal antibodies against biomarkers validated during Phase 1.

CPTC is a five-year, $104 million effort to develop proteomics tools and technologies to accelerate discovery and clinical research. In July SAIC-Frederick signed a deal with Precision Antibodies to provide antibody and antigen characterization of antibodies used in the CPTC initiative, which followed on a contract Precision won from SAIC-Frederick in 2009 to develop monoclonal antibodies for the program (PM 07/30/2010).

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.